Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-κB activation

J. Mortier, R. Frederick, L. Pochet, J. Wouters, B. Masereel, C. Ganeff, C. Remouchamps, J. Piette, E. Dejardin, P. Talaga

Research output: Contribution to journalArticlepeer-review


In this work, we aimed to build a 3D-model of NIK and to study the binding of pyrazolo[4,3-c]isoquinolines with a view to highlight the structural elements responsible for their inhibitory potency. However, in the course of this work, we unexpectedly found that the pyrazolo[4,3-c]isoquinolines initially reported as NIK inhibitors were neither inhibitors of this enzyme nor of the alternative NF-κB pathway, but were in fact inhibitors of another kinase, the TGF-β activated kinase 1 (TAK1) which is involved in the classical NF-κB pathway.
Original languageEnglish
Pages (from-to)1462-1472
Number of pages11
JournalBiochemical Pharmacology
Issue number10
Publication statusPublished - 15 May 2010


Dive into the research topics of 'Pyrazolo[4,3-c]isoquinolines as potential inhibitors of NF-κB activation'. Together they form a unique fingerprint.

Cite this